Description of Research Expertise:
Dr. Joan O’Brien has extensive expertise in the study of the genetics of ocular diseases including retinoblastoma, melanoma and glaucoma. Dr. O’Brien’s laboratory has identified numerous unique pathogenic variants in the retinoblastoma gene (RB1). This testing has allowed retinoblastoma therapy to be directed according to underlying genetic risk, and is offered nationwide at no charge to patients through NEI’s eyeGENE™ initiative. Dr. O’Brien directs a research laboratory with next generation sequencing and high-throughput, automated Sanger sequencing capabilities, which focuses on translational genetics research with an emphasis on molecular sub-classification and endophenotyping of ocular disease. Currently, Dr. O’Brien is the primary investigator on an $11.25 million 5-year Primary Open Angle African American Glaucoma Genetics (POAAGG) study.
Dr. O’Brien has 15 years of National Cancer Institute funded leadership roles in clinical trials and phenotype validation for all retinoblastoma studies administered through the Children’s Oncology Group (COG). Over the past five years, in collaboration with colleagues at UCSF, the group has discovered and characterized two novel oncogenes (GNAQ, Nature 2009 and GNA11, NEJM 2010) which regulate the MAP kinase pathway. This has allowed Dr. O’Brien’s uveal melanoma patients to have personalized and targeted therapy with MEK inhibitors, providing prolongation of life for these patients with widely metastatic melanoma.
retinoblastoma, melanoma, genetics research, glaucoma
Parik RN, Sandhu HS, Massaro-Giordano G, Goldstein SM, O'Brien JM.: Benign Reactive Lymphoid Hyperplasia of the Conjunctiva Treated with Cyclosporine. Cornea : 2017.
Salowe R, O'Keefe L, Merriam S, Lee R, Khachatryan N, Sankar P, Miller-Ellis E, Lehman A, Addis V, Murphy W, Henderer J, Maguire M, O'Brien J.: Cost and yield considerations when expanding recruitment for genetic studies: the primary open-angle African American glaucoma genetics study BMC Medical Research Methodology : 2017.
Sankar PS, Keefe LO, Choi D, Salowe R, Miller-Ellis E, Lehman A, Addis V, Ramakrishnan M, Natesh V, Whitehead G, Khachatryan G, O'Brien J: The SCHEIE Visual Field Grading System. J Clin Exp Ophthalmol 8 (3): 2017.
O’Brien JM, Salowe RJ, Fertig R, Salinas J, Pistilli M, Sankar PS, Miller-Ellis E, Lehman A, Murphy W, Homsher M, Gordon K, Ying G: Family History in the Primary Open-Angle African American Glaucoma Genetics Study Cohort. Transactions of the American Ophthalmological Society. In press : 2017.
Salowe R, O'Keefe L, Merriam S, Lee R, Khachatryan, N, Sankar P, Miller-Ellis E, Lehman A, Addis V, Murphy W, Henderer J, Maguire M, O'Brien J: Cost and Yield Considerations when Expanding Recruitment for Genetic Studies: The Primary Open-Angle African American Glaucoma Genetics Study BMC Medical Research Methodology : 2017.
Parikh R, Okeefe L, Salowe R, Mccoskey M, Wei Pan W, Sankar P, Miller-Ellis E, Addis V, Lehman A, Maguire MG, O'Brien JM: Factors Associated with Participation by African Americans in a Study of the Genetics of Glaucoma. Ethnicity and Health : 2017.
Pleet A, Sulewski M, Salowe RJ, Fertig R, Salinas J, Rhodes A, Merritt III W, Natesh V, Huang J, Gudiseva HV, Collins DW, Chavali VRM, Tapino P, Lehman A, Regina-Gigiliotti M, Miller-Ellis E, Sankar P, Ying GS, O'Brien JM: Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population. Ophthalmic Epidemiology 23 (4): 248-56,2016.
Collins DW, Gudiseva HV, Trachtman B, Bowman AS, Sagaser A, Sankar P, Miller-Ellis E, Lehman A, Addis V, O'Brien JM: Association of primary open-angle glaucoma with mitochondrial
variants and haplogroups common in African Americans. Molecular Vision 22 : 454-71,2016.
Gudiseva HV, Hansen M, Gutierrez L, Collins DW, He J, Verkuil L, Danford ID, Sagaser A, Bowman AS, Salowe R, Sankar PS, Miller-Ellis E, Lehman A, O'Brien JM: Saliva DNA quality and genotyping efficiency in a predominantly elderly population. BMC Medical Genomics 9 (17): 2016.
O'Brien JM et al: Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma: ARET0331: A Report from the Children’s Oncology Group Pediatric Blood & Cancer : 2016.
View all publications